NCT03145480 - Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 19, 2017

Primary Completion Date

September 28, 2018

Study Completion Date

September 28, 2018

Conditions

Richter Syndrome

Interventions

DRUG

Obinutuzumab

100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6

DRUG

Ibrutinib

560mg po daily

OTHER

CHOP

cyclophosphamide, doxorubicin, vincristine, and prednisone

Trial Locations (1)

Northwell Health/CLL Research and Treatment Program, New Hyde Park